Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Galaxy Biotech licenses anti-FGF2 antibodies to Roche

Executive Summary

Oncology antibody discovery company Galaxy Biotech LLC has licensed Roche exclusive worldwide rights to develop and market its preclinical antibody program--including lead candidate GALF2--against fibroblast growth factor 2 (FGF2) for cancer. The Big Pharma may also possibly work on other derivative compounds.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
Deal Status
  • Final
Deal Type
  • Alliance
    • R&D and Marketing (Licensing)

Related Companies